Premium
Higher Levels of Cystatin C in HIV / AIDS Patients with Metabolic Syndrome
Author(s) -
Dragović Gordana,
Srdić Danica,
Al Musalhi Khawla,
Soldatović Ivan,
Kušić Jovana,
Jevtović Djordje,
Nair Devaki
Publication year - 2018
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/bcpt.12919
Subject(s) - cystatin c , cart , medicine , metabolic syndrome , cystatin , human immunodeficiency virus (hiv) , antiretroviral therapy , univariate analysis , viral load , gastroenterology , immunology , multivariate analysis , obesity , creatinine , mechanical engineering , engineering
Data about Cystatin‐C levels in HIV ‐infected patients with metabolic syndrome (MetS) are still limited. Therefore, the aim of this study was to evaluate the possible correlations of serum levels of Cystatin‐C in HIV / AIDS patients treated with combined antiretroviral therapy ( cART ) with or without MetS. This cross‐sectional study included 89 HIV / AIDS Caucasian patients receiving cART at the HIV / AIDS Centre Belgrade, Serbia, divided into two groups according to the presence of MetS. Cystatin‐C and other biochemical parameters were measured using Cytokine‐Array‐I, Metabolic‐Array‐I and Metabolic‐Array‐ II , at the Department of Clinical Biochemistry, Royal Free Hospital and University College London, UK. A linear regression model was performed to evaluate which clinical and laboratory variables had an independent effect on Cystatin‐C levels in HIV / AIDS patients. There were 33 (37%) patients with MetS and 56 (63%) without MetS. Patients with and without MetS were homogenous for age, duration of cART , number of cART combinations and CD 4 + T cell count. Statistically increased Cystatin‐C levels were observed in HIV / AIDS patients with MetS ( p = 0.017), when compared to patients without MetS. Data showed a positive correlation of Cystatin‐C and C‐reactive protein ( r = 0.349, p = 0.001). Using linear regression modelling, significant correlations were obtained between Cystatin‐C and MetS in univariate analysis ( p < 0.001). Cystatin‐C levels were significantly higher in HIV / AIDS patients with MetS versus without MetS. Early assessment of MetS using Cystatin‐C as a marker may ultimately help increase the lifespan of HIV / AIDS patients, as these patients appear to be at high risk of cardiovascular diseases.